Skip to main content

Table 1 Cost savings of possible treatment outcomes per DRG and scenario [in €]

From: A budget impact analysis of bezlotoxumab versus standard of care antibiotics only in patients at high risk of CDI recurrence from a hospital management perspective in Germany

 

No case consolidation (A)

Case consolidation for SoC + bezlotoxumab (B)

Case consolidation for both treatment arms (C)

DRG

SoC

SoC + bezlo

SoC

SoC + bezlo

SoC

SoC + bezlo

B44C

  clinically cureda

720.27

1,167.96

720.27

1,167.96

720.27

1,167.96

  rCDI

1,440.55

1,888.23

1,440.55

-2,928.39

-3,376.08

-2,928.39

G67A

  clinically cureda

313.59

933.23

313.59

933.23

313.59

933.23

  rCDI

627.18

1,246.82

627.18

-894.72

-1,514.36

-894.72

G48A

  clinically cureda

675.04

1,334.05

675.04

1,334.05

675.04

1,334.05

  rCDI

1,350.08

2,009.09

1,350.08

-2,652.99

-3,312.00

-2,652.99

G52Z

  clinically cureda

832.42

1,281.95

832.42

1,281.95

832.42

1,281.95

  rCDI

1,664.83

2,114.37

1,664.83

-3,438.18

-3,887.71

-3,438.18

G77A

  clinically cureda

879.19

1,415.44

879.19

1,415.44

879.19

1,415.44

  rCDI

1,758.38

2,294.63

1,758.38

-3,732.59

-4,268.84

-3,732.59

G77B

  clinically cureda

501.43

1,009.94

501.43

1,009.94

501.43

1,009.94

  rCDI

1,002.86

1,511.37

1,002.86

-1,888.60

-2,397.11

-1,888.60

E42Z

  clinically cureda

825.51

1,275.08

825.51

1,275.08

825.51

1,275.08

  rCDI

1,651.02

2,100.59

1,651.02

-3,400.44

-3,850.01

-3,400.44

E79A

  clinically cureda

537.58

1,106.68

537.58

1,106.68

537.58

1,106.68

  rCDI

1,075.17

1,644.26

1,075.17

-1,994.88

-2,563.98

-1,994.88

T60E

  clinically cureda

417.26

980.84

417.26

980.84

417.26

980.84

  rCDI

834.51

1,398.10

834.51

-1,442.57

-2,006.15

-1,442.57

F48Z

  clinically cureda

801.91

1,246.75

801.91

1,246.75

801.91

1,246.75

  rCDI

1,603.82

2,048.66

1,603.82

-3,268.39

-3,713.23

-3,268.39

  1. Note: aFrom a hospital management perspective, the cost savings of clinically cured patients equals the cost savings of patients suffering from a rCDI without rehospitalization